Clinical trial
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera
NCT05210790 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera
- Lead sponsor
- Protagonist Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- April 1, 2022
- Completion date
- June 30, 2027
- Enrollment
- 293 (actual)
- Sites
- 184
Conditions
As the registry lists them; a condition with its own page is linked.